Fulgent Genetics
- Market cap
- 565.99M
- P/E (TTM)i
- -7.27
- P/Bi
- 0.57
- EPSi
- -1.97
- Div yieldi
- 0.00%
- 52W posi
- 40%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 57.77% -0.03pp
- Institutions
- 180
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2026-09-01
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 38 sells
| Name | Role | Stake |
|---|---|---|
| Ming Hsieh | Chairperson & CEO | 32.25% |
| Hanlin Gao | Chief Scientific Officer & Laboratory Director | 3.58% |
| Jian Xie | Chief Operating Officer | 2.11% |
| Paul Kim | Chief Financial Officer | 1.30% |
| Linda Dong | Independent Director | 0.04% |
| Michael Nohaile | Independent Director | 0.03% |
| Regina Groves | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -1,673 | $19.66 |
| 2026-09-01 | Jian Xie | Chief Operating Officer | Open Market Disposition | -2,127 | $19.66 |
| 2026-08-31 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,087 | $19.59 |
| 2026-08-31 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -4,392 | $19.59 |
| 2026-08-26 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -939 | $19.91 |
| 2026-08-26 | Jian Xie | Chief Operating Officer | Open Market Disposition | -1,193 | $19.91 |
| 2026-08-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -1,168 | $19.81 |
| 2026-08-25 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -2,949 | $19.81 |
| 2026-07-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,747 | $19.67 |
| 2026-07-25 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Sale to Issuer | -1,645 | $19.67 |
| 2026-07-25 | Jian Xie | Chief Operating Officer | Sale to Issuer | -4,361 | $19.67 |
| 2026-06-01 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -1,688 | $17.89 |
| 2026-06-01 | Jian Xie | Chief Operating Officer | Open Market Disposition | -2,146 | $17.89 |
| 2026-05-31 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,087 | $18.09 |
| 2026-05-31 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -4,392 | $18.09 |
| 2026-05-26 | Hanlin Gao | Chief Scientific Officer & Laboratory Director | Open Market Disposition | -945 | $17.60 |
| 2026-05-26 | Jian Xie | Chief Operating Officer | Open Market Disposition | -1,201 | $17.60 |
| 2026-05-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -1,168 | $17.67 |
| 2026-05-25 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -2,949 | $17.67 |
| 2026-05-13 | Regina Groves | Independent Director | Other Acquisition | +11,117 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.